Key facts
- Sudeep Pharma (BOM: 544619)’s last known valuation is $754.0M (Nov 2025).
- It has raised $40.9M; the latest was IPO ($70.5M) in Nov 2025.
- Notable investors include Motilal Oswal Mutual Fund, Nippon India Mutual Fund, Aditya Birla Sun Life AMC, Bandhan Mutual Fund, Edelweiss Mutual Fund — 12 tracked in total.
- Status: Publicly Held.
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Sudeep Pharma (BOM: 544619)
- ·The full record, as it builds
Funding rounds
No funding rounds for Sudeep Pharma (BOM: 544619) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sudeep Pharma (BOM: 544619)
Sudeep Pharma Ltd is a technology led manufacturer of excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries and is dedicated to contributing to the healthcare ecosystem. The company operates in two business verticals: Pharmaceutical, food, and nutrition. It focuses on providing refined, mineral-based single ingredients essential to the pharmaceutical, food, and nutrition industries and Specialty ingredients: It pertains manufacturing of specialty ingredients using advance technology solutions. The maximum revenue is generated from the Pharmaceutical, food, and nutrition segment. Geographically, it has presence in the United States, South America, Europe, the Middle East, Africa, and Asia-Pacific.
- Sector
- Materials and Resources
- HQ
- Vadodara, India
- Founded
- 1989
- Employees
- 740
- Website
- sudeeppharma.com/
- Ownership
- Publicly Held
Sudeep Pharma (BOM: 544619) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sudeep Pharma (BOM: 544619) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sudeep Pharma (BOM: 544619) in its N-PORT filings yet. We sweep new filings monthly.